Wedbush Downgrades Karyopharm Therapeutics (KPTI) to Neutral

January 17, 2020 6:51 AM EST
Get Alerts KPTI Hot Sheet
Price: $8.37 -4.78%

Rating Summary:
    14 Buy, 1 Hold, 1 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 18 | Down: 11 | New: 19
Trade Now! 
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.

Wedbush analyst David Nierengarten downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Outperform to Neutral with a price target of $19.00 (from $18.00).

For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.

Shares of Karyopharm Therapeutics closed at $18.83 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades